1. Home
  2. SLDP vs GERN Comparison

SLDP vs GERN Comparison

Compare SLDP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$2.82

Market Cap

675.0M

Sector

Energy

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.16

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
GERN
Founded
2011
1990
Country
United States
United States
Employees
230
258
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
675.0M
808.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLDP
GERN
Price
$2.82
$1.16
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$7.00
$2.17
AVG Volume (30 Days)
5.3M
11.6M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$48.90
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$1.04
52 Week High
$8.86
$2.01

Technical Indicators

Market Signals
Indicator
SLDP
GERN
Relative Strength Index (RSI) 40.84 38.45
Support Level $2.79 $1.05
Resistance Level $3.59 $1.30
Average True Range (ATR) 0.22 0.06
MACD -0.05 0.00
Stochastic Oscillator 11.00 39.58

Price Performance

Historical Comparison
SLDP
GERN

About SLDP Solid Power Inc.

Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: